Telix Pharmaceuticals Limited

ASX:TLX Stock Report

Market Cap: AU$6.4b

Telix Pharmaceuticals Past Earnings Performance

Past criteria checks 2/6

Telix Pharmaceuticals's earnings have been declining at an average annual rate of -6.4%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been growing at an average rate of 83.3% per year. Telix Pharmaceuticals's return on equity is 17.5%, and it has net margins of 5.5%.

Key information


Earnings growth rate


EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate83.3%
Return on equity17.5%
Net Margin5.5%
Next Earnings Update22 Aug 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Telix Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

ASX:TLX Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2457632153145
31 Dec 235035134129
30 Sep 23430-21124108
30 Jun 23357-4813563
31 Mar 23249-778991
31 Dec 22160-1048781
30 Sep 2294-1118363
30 Jun 2229-1197945
31 Mar 2218-1006340
31 Dec 218-814734
30 Sep 217-703931
30 Jun 217-593228
31 Mar 216-522826
31 Dec 205-452423
30 Sep 204-402223
30 Jun 203-361922
31 Mar 203-321722
31 Dec 193-281621
30 Sep 193-231421
30 Jun 192-191220
31 Mar 191-161119
31 Dec 180-14919
30 Sep 180-12814
30 Jun 180-1079
31 Mar 180-856
31 Dec 170-643
31 Dec 160000

Quality Earnings: TLX has a large one-off loss of A$35.1M impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: TLX became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TLX has become profitable over the past 5 years, growing earnings by -6.4% per year.

Accelerating Growth: TLX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: TLX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.7%).

Return on Equity

High ROE: TLX's Return on Equity (17.5%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.